Curiox Biosystems Co., Ltd (KOSDAQ:445680)
18,340
+30 (0.16%)
At close: Apr 4, 2025, 3:30 PM KST
Curiox Biosystems Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 24,188 | 17,909 | 5,597 | 11,003 | 7,043 |
Short-Term Investments | 4,000 | - | 3,125 | 8,816 | 809.54 |
Cash & Short-Term Investments | 28,188 | 17,909 | 8,722 | 19,819 | 7,853 |
Cash Growth | 57.39% | 105.34% | -55.99% | 152.38% | - |
Accounts Receivable | 557.32 | 1,723 | 1,832 | 1,240 | 1,146 |
Other Receivables | 132.13 | 98.19 | 68.97 | 86.29 | 86.63 |
Receivables | 689.45 | 1,821 | 1,901 | 1,326 | 1,232 |
Inventory | 1,791 | 1,621 | 2,911 | 1,759 | 595.7 |
Prepaid Expenses | 356.57 | 173.81 | 79.92 | 23.37 | 12.77 |
Other Current Assets | 1,242 | 75.54 | 336.57 | 132.05 | 197.54 |
Total Current Assets | 32,267 | 21,601 | 13,949 | 23,060 | 9,891 |
Property, Plant & Equipment | 2,095 | 2,391 | 998.06 | 543.1 | 427.33 |
Long-Term Investments | - | - | - | 0 | -0 |
Goodwill | 26,059 | 23,547 | 22,733 | 21,143 | 19,819 |
Other Intangible Assets | 9,922 | 10,056 | 10,761 | 10,969 | 11,196 |
Other Long-Term Assets | 217.71 | 203.37 | 185.77 | 78.5 | 32.68 |
Total Assets | 70,561 | 57,798 | 48,627 | 55,793 | 41,367 |
Accounts Payable | 190.32 | 330 | 929.48 | 937.19 | 127.39 |
Accrued Expenses | 595.99 | 375.03 | 537.34 | 441.11 | 201 |
Short-Term Debt | 7,398 | - | - | 30,148 | 11,857 |
Current Portion of Leases | 423.79 | 358.97 | 219.12 | 56.96 | 25.65 |
Current Unearned Revenue | 585.74 | 669.72 | 539.41 | 286.02 | 107.22 |
Other Current Liabilities | 10,723 | 982.85 | 609.44 | 411.63 | 353.16 |
Total Current Liabilities | 19,918 | 2,717 | 2,835 | 32,281 | 12,672 |
Long-Term Debt | - | - | - | - | 126.73 |
Long-Term Leases | 319.98 | 606.19 | 168.09 | 241.58 | 157.86 |
Long-Term Deferred Tax Liabilities | 1,685 | 1,592 | 1,764 | 1,564 | 1,734 |
Other Long-Term Liabilities | 0 | - | 0 | 0 | -0 |
Total Liabilities | 21,923 | 4,915 | 4,767 | 34,087 | 14,690 |
Common Stock | 8,062 | 4,011 | 3,284 | 543 | 543 |
Additional Paid-In Capital | 85,431 | 88,965 | 71,651 | 27,944 | 27,944 |
Retained Earnings | -53,556 | -45,466 | -35,426 | -23,931 | -9,407 |
Comprehensive Income & Other | 8,695 | 5,369 | 4,344 | 1,027 | -1,805 |
Total Common Equity | 48,632 | 52,879 | 43,853 | 5,582 | 17,274 |
Minority Interest | 5.06 | 4.93 | 7.82 | 10.82 | 10.13 |
Shareholders' Equity | 48,637 | 52,883 | 43,861 | 21,707 | 26,677 |
Total Liabilities & Equity | 70,561 | 57,798 | 48,627 | 55,793 | 41,367 |
Total Debt | 8,142 | 965.16 | 387.21 | 30,446 | 12,168 |
Net Cash (Debt) | 20,045 | 16,944 | 8,334 | -10,627 | -4,315 |
Net Cash Growth | 18.30% | 103.30% | - | - | - |
Net Cash Per Share | 1246.49 | 1184.67 | 1174.42 | -1630.92 | -662.17 |
Filing Date Shares Outstanding | 16.12 | 16.04 | 13.14 | 6.52 | 6.52 |
Total Common Shares Outstanding | 16.12 | 16.04 | 13.14 | 6.52 | 6.52 |
Working Capital | 12,349 | 18,884 | 11,115 | -9,221 | -2,781 |
Book Value Per Share | 3016.12 | 3295.64 | 3337.89 | 856.64 | 2651.04 |
Tangible Book Value | 12,651 | 19,276 | 10,359 | -26,530 | -13,741 |
Tangible Book Value Per Share | 784.63 | 1201.37 | 788.46 | -4071.57 | -2108.88 |
Machinery | 2,837 | 2,440 | 1,219 | 740.14 | 704.78 |
Construction In Progress | 102.38 | - | - | - | - |
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.